1044.3500 -5.25 (-0.50%)
NSE Nov 20, 2026 12:25 PM
Volume: 73,859
 

1044.35
-0.50%
Deven Choksey
Alembic Pharma is expected to maintain steady growth momentum supported by its expanding complex generics portfolio in the US, sustained traction in Ex-US markets, and a gradual recovery in the domestic formulations business.
Number of FII/FPI investors increased from 179 to 189 in Sep 2026 qtr.
More from Alembic Pharmaceuticals Ltd.
Recommended